This is the highest level of accreditation granted by the PHA. The designation recognizes the high quality and depth of resources available at
'This is an important recognition of our multidisciplinary team's skill and dedication in diagnosing and treating patients with this rare and complex lung condition,' said
UC Davis first received accreditation in 2016, one of the early programs to be recognized by the PHA.
Pulmonary hypertension is a lung disorder in which blood pressure in the pulmonary artery rises above normal levels. Symptoms of the rare disease include shortness of breath, fatigue, chest pressure or pain, dizziness with exertion and swelling in the ankles.
The evaluation of patients with pulmonary hypertension is a meticulous process. It requires a series of tests and direct measurement of the pressure in the heart and lungs before the correct treatment can be selected. While not curable, pulmonary hypertension is manageable with the right treatment.
'We are very pleased that the PHA has again designated our program a Center of
The Pulmonary Hypertension Program's multidisciplinary team of pulmonologists, cardiologists, radiologists, nurse specialists, pharmacists and respiratory therapists work together to provide state-of-the-art care and advanced therapies. The program also provides access to newer treatments through research protocols.
Contact:
Tel: 916-752-6394
(C) 2021 Electronic News Publishing, source